CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)

Authors: Manmeet Ahluwalia, Michael J Ciesielski, Ajay Abad, David A Reardon, Robert Aiken, Marissa Barbaro, Kaylyn Sinicrope, David Peereboom, Yazmin Odia, Andrew Brenner, Vyshak Venur, Ahmed Belal, Jingxin Qiu, Atulya Khosla, Cathy Schilero, Danielle Casucci, Laszlo Mechtler, Robert Fenstermaker

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.252

Source: Full article

CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)

Abstract